LabConnect Announces Global Sample Processing Network
Seattle, January 22, 2019 (Business Wire) – LabConnect, a leading global provider of central laboratory and support services for biopharmaceutical, medical device, and contract research organizations, is pleased to announce a new service: LabConnect’s global sample processing network (GSPN). This GSPN will offer a comprehensive global solution for sample preparation and processing requirements.
Given the rapid growth in immuno-oncology and cell gene therapies, high-quality and expeditious sample processing is required within today’s trials. Balancing turnaround time requirements with the desire for processing consistency across global sites is an industry-wide challenge.
With more worldwide locations than any other central laboratory services provider, LabConnect addresses this challenge by significantly minimizing shipping time from site to processing lab, optimizing viability for time-sensitive samples. Proprietary packaging, standardized analyst certification and centralized performance monitoring combine to ensure global consistency. Additionally, LabConnect’s web portal allows easy access to study-wide sample processing quality metrics. LabConnect’s GSPN supports global research protocols by offering reliable worldwide sample processing.
Jeff Mayhew, chief development officer at LabConnect says, “LabConnect has recognized the growing need for high quality sample processing in the industry’s increasingly complex studies. GSPN is our innovative approach to addressing these evolving demands. GSPN combines our extensive global footprint with our global expertise in sample processing, offering the unique ability to meet the most challenging of study requirements.”
About LabConnect
Founded in 2002, LabConnect comprises a network of global central laboratories with services including routine and esoteric laboratory testing, clinical kit building, sample management, biorepository, and scientific operations support services for biopharmaceutical, medical device, and contract research organizations around the world. Learn more at labconnectllc.com or connect with LabConnect on LinkedIn.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
